Pepinemab (VX15/2503), a humanized IgG4 monoclonal antibody against SEMA4D, is being studied in a phase I/II clinical trial in combination with avelumab in patients with advanced-stage NSCLC (NCT03268057). Here, SEMA4D is linked to non-small cell lung carcinoma.